The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Nonstimulant ADHD Treatment Drugs Market Research Report 2025
Synopsis
Nonstimulant ADHD treatment drugs are an alternative to stimulant medications for managing Attention Deficit Hyperactivity Disorder (ADHD). These medications include substances like atomoxetine (Strattera), guanfacine (Intuniv), and clonidine (Kapvay). Unlike stimulants, which increase dopamine and norepinephrine levels rapidly, nonstimulants work more gradually by modulating neurotransmitters subtly over time. They are particularly useful for patients who may not respond well to stimulants, or who experience significant side effects. Nonstimulants are noted for their ability to improve concentration, decrease impulsivity, and reduce hyperactivity, with a lower potential for abuse. They can be a good option for individuals seeking a medication regimen with a different side effect profile or mechanism of action compared to traditional stimulant therapies.
The global Nonstimulant ADHD Treatment Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Nonstimulant ADHD Treatment Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Nonstimulant ADHD Treatment Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Nonstimulant ADHD Treatment Drugs in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Nonstimulant ADHD Treatment Drugs include Eli Lilly, Takeda, Novartis, Neos Therapeutics, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, CTFH, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Nonstimulant ADHD Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonstimulant ADHD Treatment Drugs.
The Nonstimulant ADHD Treatment Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nonstimulant ADHD Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nonstimulant ADHD Treatment Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Takeda
Novartis
Neos Therapeutics
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
CTFH
Segment by Type
Atomoxitine
Guanfacine
Clonidine
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nonstimulant ADHD Treatment Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Nonstimulant ADHD treatment drugs are an alternative to stimulant medications for managing Attention Deficit Hyperactivity Disorder (ADHD). These medications include substances like atomoxetine (Strattera), guanfacine (Intuniv), and clonidine (Kapvay). Unlike stimulants, which increase dopamine and norepinephrine levels rapidly, nonstimulants work more gradually by modulating neurotransmitters subtly over time. They are particularly useful for patients who may not respond well to stimulants, or who experience significant side effects. Nonstimulants are noted for their ability to improve concentration, decrease impulsivity, and reduce hyperactivity, with a lower potential for abuse. They can be a good option for individuals seeking a medication regimen with a different side effect profile or mechanism of action compared to traditional stimulant therapies.
The global Nonstimulant ADHD Treatment Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Nonstimulant ADHD Treatment Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Nonstimulant ADHD Treatment Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Nonstimulant ADHD Treatment Drugs in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Nonstimulant ADHD Treatment Drugs include Eli Lilly, Takeda, Novartis, Neos Therapeutics, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, CTFH, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Nonstimulant ADHD Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonstimulant ADHD Treatment Drugs.
The Nonstimulant ADHD Treatment Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nonstimulant ADHD Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nonstimulant ADHD Treatment Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Takeda
Novartis
Neos Therapeutics
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
CTFH
Segment by Type
Atomoxitine
Guanfacine
Clonidine
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nonstimulant ADHD Treatment Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Atomoxitine
1.2.3 Guanfacine
1.2.4 Clonidine
1.2.5 Other
1.3 Market by Application
1.3.1 Global Nonstimulant ADHD Treatment Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nonstimulant ADHD Treatment Drugs Market Perspective (2019-2030)
2.2 Global Nonstimulant ADHD Treatment Drugs Growth Trends by Region
2.2.1 Global Nonstimulant ADHD Treatment Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Nonstimulant ADHD Treatment Drugs Historic Market Size by Region (2019-2024)
2.2.3 Nonstimulant ADHD Treatment Drugs Forecasted Market Size by Region (2025-2030)
2.3 Nonstimulant ADHD Treatment Drugs Market Dynamics
2.3.1 Nonstimulant ADHD Treatment Drugs Industry Trends
2.3.2 Nonstimulant ADHD Treatment Drugs Market Drivers
2.3.3 Nonstimulant ADHD Treatment Drugs Market Challenges
2.3.4 Nonstimulant ADHD Treatment Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nonstimulant ADHD Treatment Drugs Players by Revenue
3.1.1 Global Top Nonstimulant ADHD Treatment Drugs Players by Revenue (2019-2024)
3.1.2 Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Nonstimulant ADHD Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Nonstimulant ADHD Treatment Drugs Revenue
3.4 Global Nonstimulant ADHD Treatment Drugs Market Concentration Ratio
3.4.1 Global Nonstimulant ADHD Treatment Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonstimulant ADHD Treatment Drugs Revenue in 2023
3.5 Global Key Players of Nonstimulant ADHD Treatment Drugs Head office and Area Served
3.6 Global Key Players of Nonstimulant ADHD Treatment Drugs, Product and Application
3.7 Global Key Players of Nonstimulant ADHD Treatment Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nonstimulant ADHD Treatment Drugs Breakdown Data by Type
4.1 Global Nonstimulant ADHD Treatment Drugs Historic Market Size by Type (2019-2024)
4.2 Global Nonstimulant ADHD Treatment Drugs Forecasted Market Size by Type (2025-2030)
5 Nonstimulant ADHD Treatment Drugs Breakdown Data by Application
5.1 Global Nonstimulant ADHD Treatment Drugs Historic Market Size by Application (2019-2024)
5.2 Global Nonstimulant ADHD Treatment Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Nonstimulant ADHD Treatment Drugs Market Size (2019-2030)
6.2 North America Nonstimulant ADHD Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024)
6.4 North America Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nonstimulant ADHD Treatment Drugs Market Size (2019-2030)
7.2 Europe Nonstimulant ADHD Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024)
7.4 Europe Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size (2019-2030)
8.2 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nonstimulant ADHD Treatment Drugs Market Size (2019-2030)
9.2 Latin America Nonstimulant ADHD Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024)
9.4 Latin America Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size (2019-2030)
10.2 Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Nonstimulant ADHD Treatment Drugs Introduction
11.1.4 Eli Lilly Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Takeda
11.2.1 Takeda Company Details
11.2.2 Takeda Business Overview
11.2.3 Takeda Nonstimulant ADHD Treatment Drugs Introduction
11.2.4 Takeda Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.2.5 Takeda Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Nonstimulant ADHD Treatment Drugs Introduction
11.3.4 Novartis Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Neos Therapeutics
11.4.1 Neos Therapeutics Company Details
11.4.2 Neos Therapeutics Business Overview
11.4.3 Neos Therapeutics Nonstimulant ADHD Treatment Drugs Introduction
11.4.4 Neos Therapeutics Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.4.5 Neos Therapeutics Recent Development
11.5 Amneal Pharmaceuticals
11.5.1 Amneal Pharmaceuticals Company Details
11.5.2 Amneal Pharmaceuticals Business Overview
11.5.3 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Introduction
11.5.4 Amneal Pharmaceuticals Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.5.5 Amneal Pharmaceuticals Recent Development
11.6 Noven Pharmaceuticals
11.6.1 Noven Pharmaceuticals Company Details
11.6.2 Noven Pharmaceuticals Business Overview
11.6.3 Noven Pharmaceuticals Nonstimulant ADHD Treatment Drugs Introduction
11.6.4 Noven Pharmaceuticals Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.6.5 Noven Pharmaceuticals Recent Development
11.7 Purdue Parma
11.7.1 Purdue Parma Company Details
11.7.2 Purdue Parma Business Overview
11.7.3 Purdue Parma Nonstimulant ADHD Treatment Drugs Introduction
11.7.4 Purdue Parma Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.7.5 Purdue Parma Recent Development
11.8 CTFH
11.8.1 CTFH Company Details
11.8.2 CTFH Business Overview
11.8.3 CTFH Nonstimulant ADHD Treatment Drugs Introduction
11.8.4 CTFH Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
11.8.5 CTFH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Atomoxitine
Table 3. Key Players of Guanfacine
Table 4. Key Players of Clonidine
Table 5. Key Players of Other
Table 6. Global Nonstimulant ADHD Treatment Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Nonstimulant ADHD Treatment Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Nonstimulant ADHD Treatment Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Nonstimulant ADHD Treatment Drugs Market Share by Region (2019-2024)
Table 10. Global Nonstimulant ADHD Treatment Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Nonstimulant ADHD Treatment Drugs Market Share by Region (2025-2030)
Table 12. Nonstimulant ADHD Treatment Drugs Market Trends
Table 13. Nonstimulant ADHD Treatment Drugs Market Drivers
Table 14. Nonstimulant ADHD Treatment Drugs Market Challenges
Table 15. Nonstimulant ADHD Treatment Drugs Market Restraints
Table 16. Global Nonstimulant ADHD Treatment Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Nonstimulant ADHD Treatment Drugs Market Share by Players (2019-2024)
Table 18. Global Top Nonstimulant ADHD Treatment Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonstimulant ADHD Treatment Drugs as of 2023)
Table 19. Ranking of Global Top Nonstimulant ADHD Treatment Drugs Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Nonstimulant ADHD Treatment Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Global Key Players of Nonstimulant ADHD Treatment Drugs, Headquarters and Area Served
Table 22. Global Key Players of Nonstimulant ADHD Treatment Drugs, Product and Application
Table 23. Global Key Players of Nonstimulant ADHD Treatment Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Nonstimulant ADHD Treatment Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global Nonstimulant ADHD Treatment Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global Nonstimulant ADHD Treatment Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Application (2019-2024)
Table 31. Global Nonstimulant ADHD Treatment Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Application (2025-2030)
Table 33. North America Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. Eli Lilly Company Details
Table 49. Eli Lilly Business Overview
Table 50. Eli Lilly Nonstimulant ADHD Treatment Drugs Product
Table 51. Eli Lilly Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 52. Eli Lilly Recent Development
Table 53. Takeda Company Details
Table 54. Takeda Business Overview
Table 55. Takeda Nonstimulant ADHD Treatment Drugs Product
Table 56. Takeda Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 57. Takeda Recent Development
Table 58. Novartis Company Details
Table 59. Novartis Business Overview
Table 60. Novartis Nonstimulant ADHD Treatment Drugs Product
Table 61. Novartis Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 62. Novartis Recent Development
Table 63. Neos Therapeutics Company Details
Table 64. Neos Therapeutics Business Overview
Table 65. Neos Therapeutics Nonstimulant ADHD Treatment Drugs Product
Table 66. Neos Therapeutics Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 67. Neos Therapeutics Recent Development
Table 68. Amneal Pharmaceuticals Company Details
Table 69. Amneal Pharmaceuticals Business Overview
Table 70. Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Product
Table 71. Amneal Pharmaceuticals Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 72. Amneal Pharmaceuticals Recent Development
Table 73. Noven Pharmaceuticals Company Details
Table 74. Noven Pharmaceuticals Business Overview
Table 75. Noven Pharmaceuticals Nonstimulant ADHD Treatment Drugs Product
Table 76. Noven Pharmaceuticals Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 77. Noven Pharmaceuticals Recent Development
Table 78. Purdue Parma Company Details
Table 79. Purdue Parma Business Overview
Table 80. Purdue Parma Nonstimulant ADHD Treatment Drugs Product
Table 81. Purdue Parma Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 82. Purdue Parma Recent Development
Table 83. CTFH Company Details
Table 84. CTFH Business Overview
Table 85. CTFH Nonstimulant ADHD Treatment Drugs Product
Table 86. CTFH Revenue in Nonstimulant ADHD Treatment Drugs Business (2019-2024) & (US$ Million)
Table 87. CTFH Recent Development
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
Table 91. Authors List of This Report
List of Figures
Figure 1. Nonstimulant ADHD Treatment Drugs Picture
Figure 2. Global Nonstimulant ADHD Treatment Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Nonstimulant ADHD Treatment Drugs Market Share by Type: 2023 VS 2030
Figure 4. Atomoxitine Features
Figure 5. Guanfacine Features
Figure 6. Clonidine Features
Figure 7. Other Features
Figure 8. Global Nonstimulant ADHD Treatment Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 9. Global Nonstimulant ADHD Treatment Drugs Market Share by Application: 2023 VS 2030
Figure 10. Hospital Pharmacy Case Studies
Figure 11. Retail Pharmacy Case Studies
Figure 12. Nonstimulant ADHD Treatment Drugs Report Years Considered
Figure 13. Global Nonstimulant ADHD Treatment Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Nonstimulant ADHD Treatment Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Nonstimulant ADHD Treatment Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Nonstimulant ADHD Treatment Drugs Market Share by Players in 2023
Figure 17. Global Top Nonstimulant ADHD Treatment Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonstimulant ADHD Treatment Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Nonstimulant ADHD Treatment Drugs Revenue in 2023
Figure 19. North America Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Nonstimulant ADHD Treatment Drugs Market Share by Country (2019-2030)
Figure 21. United States Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Nonstimulant ADHD Treatment Drugs Market Share by Country (2019-2030)
Figure 25. Germany Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Share by Region (2019-2030)
Figure 33. China Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Nonstimulant ADHD Treatment Drugs Market Share by Country (2019-2030)
Figure 41. Mexico Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Nonstimulant ADHD Treatment Drugs Market Share by Country (2019-2030)
Figure 45. Turkey Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. UAE Nonstimulant ADHD Treatment Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Eli Lilly Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 49. Takeda Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 51. Neos Therapeutics Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 52. Amneal Pharmaceuticals Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 53. Noven Pharmaceuticals Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 54. Purdue Parma Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 55. CTFH Revenue Growth Rate in Nonstimulant ADHD Treatment Drugs Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
